Of note, the orally bioavailable rapamycin derivative everolimus was clinically efficacious against advanced renal cell carcinoma patients, who progressed on pan-receptor tyrosine kinase inhibitors, such as sunitinib or sorafenib (41). Here, NTRK1 is linked to renal cell carcinoma.